Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Contact
Bahnhofstrasse 20
ZugCH-6300
CHET: +41 417113960
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,223.93 | 315.19 | 3.99% |
| DAX 40 | 23,993.38 | 1,071.79 | 4.68% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,588.71 | 239.92 | 2.32% |
| HKSE | 25,845.24 | 728.71 | 2.90% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |